Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Yukiko Shimoda"'
Autor:
Masahiro Torasawa, Tatsuya Yoshida, Yuki Takeyasu, Yukiko Shimoda, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Kazuhisa Takahashi, Yuichiro Ohe
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12388-12401 (2023)
Abstract Background It is still unclear whether patients with advanced non‐small cell lung cancer (NSCLC), with disease progression after initial immune checkpoint inhibitor (ICI) therapy, would benefit from ICIs readministration. Patients and Meth
Externí odkaz:
https://doaj.org/article/7ac7d1fe4d974671b57fe0cc9e30f8bb
Autor:
Tetsuya Suzuki, Yukiko Shimoda, Katsuji Teruya, Hiroyuki Gatanaga, Yoshimi Kikuchi, Shinichi Oka, Koji Watanabe
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-3 (2019)
Abstract Background Fibrosing interstitial lung disease is the poor prognostic non-infectious lung disease by unknown etiology. Here, we present one case developing interstitial pneumonia with fibrosis after treatment of pneumocystis pneumonia (PCP)
Externí odkaz:
https://doaj.org/article/81e004644d804922b94919c88d0bbd09
Autor:
Baba, Shogo a, Kawasaki, Tadatoshi b, Hirano, Satoshi c, Nakamura, Toru c, Asano, Toshimichi c, Okazaki, Ryo c, Yoshida, Koji d, Kawase, Tomoya d, e, Kurahara, Hiroshi f, Oi, Hideyuki f, Yokoyama, Masaya g, h, Kita, Junji g, Imura, Johji i, Kinoshita, Kazuya g, Kondo, Shunsuke j, k, l, Okada, Mao j, k, Satake, Tomoyuki m, Igawa, Yukiko Shimoda n, Yoshida, Tatsuya j, n, Yamaguchi, Hiroki o, Ando, Yoriko o, p, Mizunuma, Mika o, Ichikawa, Yuki o, p, Hida, Kyoko q, Nishihara, Hiroshi r, ∗, Kato, Yasutaka a, r, ∗
Publikováno v:
In eClinicalMedicine December 2024 78
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yukiko Shimoda, Ryota Shibaki, Tatsuya Yoshida, Shuji Murakami, Masayuki Shirasawa, Masahiro Torasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe, Noriko Motoi
Publikováno v:
Clinical Lung Cancer. 23:477-486
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e06d65915500596d2461858ef2e161a
https://doi.org/10.1016/j.cllc.2022.04.001
https://doi.org/10.1016/j.cllc.2022.04.001
Autor:
Yukiko Shimoda, Tatsuya Yoshida, Jun Miyakoshi, Masahiro Torasawa, Akiko Tateishi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Publikováno v:
Cancer Immunology, Immunotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1e1cad51f2a408dd5744248ce1fa9e8
https://doi.org/10.1007/s00262-023-03429-z
https://doi.org/10.1007/s00262-023-03429-z
Autor:
Yuichiro Ohe, Tatsuya Yoshida, Noboru Yamamoto, Takashi Kubo, Noriko Motoi, Yuji Matsumoto, Kouya Shiraishi, Yuki Shinno, Hidehito Horinouchi, Masayuki Shirasawa, Yasushi Goto, Koichi Goto, Sachiyo Mitani, Daisuke Takayanagi, Takashi Kohno, Yusuke Okuma, Hitoshi Ichikawa, Shingo Matsumoto, Shun-ichi Watanabe, Ken Masuda, Yukiko Shimoda
Publikováno v:
Journal of Thoracic Oncology. 16:2078-2090
Introduction Programmed death-ligand 1 (PD-L1) expression is not a completely reliable predictive marker of the efficacy of anti–programmed cell death protein-1 (PD-1)/PD-L1 therapy in patients with advanced NSCLC. Immune-related tumor microenviron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d2b94d9787d54c0d75af594f6efe68
https://doi.org/10.1016/j.jtho.2021.07.027
https://doi.org/10.1016/j.jtho.2021.07.027
Autor:
Tatsuya Yoshida, Yasushi Goto, Takaaki Mizuno, Yuji Matsumoto, Yusuke Okuma, Noboru Yamamoto, Noriko Motoi, Hitomi Jo, Yasushi Yatabe, Masayuki Shirasawa, Yukiko Shimoda, Yuichiro Ohe, Yuki Shinno, Hidehito Horinouchi
Publikováno v:
Anticancer Research. 41:5739-5747
BACKGROUND/AIM Programmed death-ligand 1 (PD-L1) expression on tumor cells is a predictive biomarker of programmed cell death 1 (PD-1) blockade therapy. This study sought to clarify predictors of the efficacy of nivolumab in non-small cell lung cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a974703a33a5409b1d50906c5cb176c2
https://doi.org/10.21873/anticanres.15390
https://doi.org/10.21873/anticanres.15390
Autor:
Masahiro Torasawa, Tatsuya Yoshida, Shigehiro Yagishita, Yukiko Shimoda, Masayuki Shirasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Kazuhisa Takahashi, Yuichiro Ohe
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 167
Nivolumab and pembrolizumab have been the standard of care in patients with previously treated advanced non-small cell lung cancer (NSCLC). This study aimed to compare the efficacy and safety of nivolumab and pembrolizumab.We retrospectively reviewed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8b66992f8ece7191bbca65e4d498495
https://pubmed.ncbi.nlm.nih.gov/35397298
https://pubmed.ncbi.nlm.nih.gov/35397298
Autor:
Yukiko Shimoda, Jun Miyakoshi, Tatsuya Yoshida, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Publikováno v:
Annals of Oncology. 33:S482-S483
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56931190d1c6269e7c34278c4ea7557f
https://doi.org/10.1016/j.annonc.2022.05.105
https://doi.org/10.1016/j.annonc.2022.05.105